Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial

NCT ID: NCT03735446

Last Updated: 2019-06-12

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1
• Total Enrollment: 2 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-01-18
• Study Completion Date: 2019-03-29

Brief Summary

This research study is studying a targeted therapy combined with chemotherapy as a possible treatment for acute myeloid leukemia (AML) or high risk myelodysplastic syndrome (MDS).

The drugs involved in this study are:

• Prexasertib (LY2606368)
• Mitoxantrone
• Etoposide
• Cytarabine

Detailed Description

This research study is a Phase I clinical trial, which tests the safety of an investigational drug or combination of drugs and also tries to define the appropriate dose of the investigational intervention to use for further studies. "Investigational" means that the drug is being studied.

The FDA (the U.S. Food and Drug Administration) has not approved prexasertib as a treatment for any disease. Prexasertib is a checkpoint kinase 1 (CHK1) inhibitor that is being developed as a treatment for patients with advanced cancer. CHK1 inhibitors work by preventing cancer cells from being able to repair damaged DNA (one of the building blocks of a cell) which then leads to cell death.

The drugs mitoxantrone, etoposide, and cytarabine (MEC) have all been approved by the FDA. MEC is a standard chemotherapy treatment option, commonly used for AML that has not responded to other standard treatment or returned following standard treatment.

In this research study, the investigators are combining prexasertib with MEC therapy to test if it is a safe treatment for AML or MDS that has returned or not responded to standard treatment.

Conditions

Acute Myeloid Leukemia; Myelodysplastic Syndromes

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Prexasertib+MEC

• Cytarabine is administered intravenously on days 1-5.
• Etoposide is administered intravenously on days 1-5.
• Mitoxantrone is administered intravenously on days 1-5.
• Prexasertib is administered intravenously on days 1, 3, and 5.

Group Type: EXPERIMENTAL

Prexasertib

Intervention Type: DRUG

Checkpoint kinase 1 (CHK1) inhibitor

Mitoxantrone

Intervention Type: DRUG

Standard chemotherapy (topoisomerase inhibitor)

Etoposide

Intervention Type: DRUG

Standard chemotherapy (topoisomerase II inhibitor)

Cytarabine

Intervention Type: DRUG

Standard chemotherapy (anti-metabolite)

Interventions

Prexasertib

Checkpoint kinase 1 (CHK1) inhibitor

Intervention Type: DRUG

Mitoxantrone

Standard chemotherapy (topoisomerase inhibitor)

Intervention Type: DRUG

Etoposide

Standard chemotherapy (topoisomerase II inhibitor)

Intervention Type: DRUG

Cytarabine

Standard chemotherapy (anti-metabolite)

Intervention Type: DRUG

Other Intervention Names

LY2606368; Novantrone

Eligibility Criteria

Inclusion Criteria

• Patients must have histologically confirmed relapsed or refractory acute myeloid leukemia (AML) or high risk myelodysplastic syndrome (MDS) diagnosed per WHO criteria.
• For refractory AML: refractory as defined per International Working Group (IWG) criteria. Refractory patients must have had ≤ 2 prior induction regimens (hydroxyurea is not considered a prior treatment regimen). "5+2" reinduction at day 14 is not considered a second regimen.
• For relapsed AML: relapse as defined by IWG criteria. Relapsed patients must be first or second relapse (hydroxyurea is not considered a prior treatment regimen).
• For patients with MDS, ≥ 10% myeloblasts in the bone marrow, and no more than 2 prior treatment regimens (hydroxyurea is not considered a prior treatment regimen).
• Patients must be medically eligible to receive mitoxantrone, etoposide, and cytarabine (MEC) therapy.
• Age ≥ 18 years
• ECOG performance status ≤ 2 (Karnofsky ≥60%)
• Patients must have adequate organ function as defined below:

• Total bilirubin ≤ 1.5 × institutional upper limit of normal (ULN), OR
• Total bilirubin ≤ 2 × institutional ULN if the participant has a history of Gilbert's syndrome.
• AST(SGOT)/ALT(SGPT) ≤ 2.5 × institutional ULN, OR
• AST(SGOT)/ALT(SGPT) ≤ 5 × institutional ULN if elevation is a result of leukemia
• Serum creatinine ≤ 1.5 × institutional ULN, OR
• Creatinine Clearance ≥ 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal (calculated via the Cockcroft-Gault equation).
• Left ventricular ejection fraction (LVEF) ≥ 50% on screening echocardiogram (ECHO) or multigated acquisition scan (MUGA).
• QTcF value of ≤ 450 msec on screening electrocardiogram (ECG).
• Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 4 months after treatment. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of study therapy administration. A negative serum pregnancy test is required for women of child-bearing potential.
• Ability to understand and the willingness to sign a written informed consent document.
• Patients may have had a prior autologous or allogeneic transplant if there is at least 100 days between transplant and screening, and there is no evidence of active graft-versus-host-disease (GvHD) or ongoing requirement for immunosuppressive therapy.

Exclusion Criteria

• Patients who have had chemotherapy, other investigational therapy, radiotherapy, or immune therapy within 2 weeks prior to the first dose of study medication. Hydroxyurea is allowed with no required washout and may be administered up to day 5 of protocol therapy.
• Patients previously treated with MEC chemotherapy.
• Patients who have received a tyrosine kinase inhibitor (TKI) within 5 half-lives of day 1.
• Patients who have had major surgery within 4 weeks prior to the first dose of study medication.
• Patients with acute promyelocytic leukemia.
• Patients with a known personal or family history of long QT syndrome.
• Patients with known CNS leukemia involvement.
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to prexasertib, mitoxantrone, etoposide, or cytarabine.
• Patients with a history of a secondary malignancy, with the following exceptions:

• Malignancies that have been curatively treated and have not recurred within the past 2 years
• Adequately treated carcinoma in situ of any type
• Curatively treated non-melanoma skin cancers
• Any other malignancy that has been curatively treated with a low likelihood of recurrence as judged by the treating investigator and agreed upon with the overall principal investigator prior to study entry
• Patients with other secondary malignancies may be allowed to enroll with agreement from the overall principal investigator.
• Uncontrolled intercurrent illness including, but not limited to: uncontrolled active infection, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• Pregnant women are excluded from this study because prexasertib, mitoxantrone, etoposide, and cytarabine are anti-cancer agents with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with the study agents, breastfeeding should be discontinued if the mother is treated with prexasertib, mitoxantrone, etoposide, or cytarabine.
• Patients who are known to be seropositive for human immunodeficiency virus (HIV) or hepatitis B or C.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Eli Lilly and Company

INDUSTRY

Sponsor Role: collaborator

Dana-Farber Cancer Institute

OTHER

Sponsor Role: lead

Responsible Party

Eric Stephen Winer

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Eric S Winer, MD

Role: PRINCIPAL_INVESTIGATOR

Dana-Farber Cancer Institute

Locations

Dana Farber Cancer Institute

Boston, Massachusetts, United States

Countries

United States

Other Identifiers

18-468

Identifier Type: -

Identifier Source: org_study_id